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Clinical usefulness of doxorubicin (DOX) is limited by the occurrence of multidrug resistance (MDR) associated with the presence of
membrane transporters (e.g. P-glycoprotein, MRP1) responsible for the active efflux of drugs out of resistant cells. Doxorubicin is a
well-known bioreductive antitumour drug. Its ability to undergo a one-electron reduction by cellular oxidoreductases is related to the
formation of an unstable semiquionone radical and followed by the production of reactive oxygen species. There is an increasing
body of evidence that the activation of bioreductive drugs could result in the alkylation or crosslinking binding of DNA and lead to the
significant increase in the cytotoxic activity against tumour cells. The aim of this study was to examine the role of reductive activation
of DOX by the human liver NADPH cytochrome P450 reductase (CPR) in increasing its cytotoxic activity especially in regard to
MDR tumour cells. It has been evidenced that, upon CPR catalysis, DOX underwent only the redox cycling (at low NADPH
concentration) or a multistage chemical transformation (at high NADPH concentration). It was also found, using superoxide
dismutase (SOD), that the first stage undergoing reductive activation according to the mechanism of the redox cycling had the key
importance for the metabolic conversion of DOX. In the second part of this work, the ability of DOX to inhibit the growth of human
promyelocytic-sensitive leukaemia HL60 cell line as well as its MDR sublines exhibiting two different phenotypes of MDR related to
the overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX) was studied in the presence of exogenously added CPR.
Our assays showed that the presence of CPR catalysing only the redox cycling of DOX had no effect in increasing its cytotoxicity
against sensitive and MDR tumour cells. In contrast, an important increase in cytotoxic activity of DOX after its reductive conversion
by CPR was observed against HL60 as well as HL60/VINC and HL60/DOX cells.
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The anthracycline antitumour agent, doxorubicin (DOX), is one
of the most effective drugs, currently available for the treatment of
various human neoplastic diseases including leukaemias, lympho-
mas, sarcomas, carcinomas and breast cancers (Wiernik and
Dutcher, 1992; Lown, 1993). However, their clinical usefulness
is limited by the occurrence of multidrug resistance (MDR) asso-
ciated with the presence of membrane transporters (e.g. P-glyco-
protein, MRP1), belonging to the ATP-binding cassette protein
family (Gottesman and Pastan, 1993; Germann, 1996; Marie et al,
1996; Borst et al, 2000). These transporters are responsible for the
active ATP-dependent efflux of drugs out of resistant cells
resulting in the decreased intracellular accumulation insufficient
to inhibit resistant cell proliferation (Zaman et al, 1994; Paul et al,
1996).
Different mechanisms have been proposed for anthracycline
antitumour effects including DNA intercalation with consequent
inhibition of DNA biosynthesis, free radical formation with
induction of DNA damage, alkylation of DNA and DNA cross-
linking, inhibition of topoisomerase II, activation of signalling
pathways and apoptosis (for a recent review, see Gewirtz, 1999).
Free radical generation by DOX is linked to its one-electron
reduction by cellular oxidoreductases. This process comprises the
one-electron transfer from reduced nucleotides, which converts
the anthracycline molecule to a semiquinone radical form DOX
K
.
The process of a one-electron transfer is catalysed by a range of
cellular oxidoreductases, mainly NADH dehydrogenase, NADPH
cytochrome P450 reductase (CPR), xanthine oxidase (Mordente
et al, 2001; Pawłowska et al, 2003) and nitric oxide synthase
(Vasquez-Vivar et al, 1997; Garner et al, 1999). Subsequent
nonenzymatic semiquinone radical reoxidation by molecular
oxygen can form reactive oxygen species (O2
K
,
K
OH, H2O2,
1O2)
that interact with various cellular macromolecules, for example,
DNA (Begleiter and Leith, 1990), lipids and other cell constituents
(Shinha, 1989). Doxorubicin-induced generation of reactive
oxygen species was proposed to be a major mechanism of its
dose-dependent cardiotoxicity (Lee et al, 1991; Havlin, 1992; Gille
and Nohl, 1997). It is generally viewed that the reductive
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smetabolism of DOX could also lead to the deglycosylation of the
drug catalysed by cellular oxidoreductases (mentioned above) via
a one-electron transfer or to the formation of doxorubicinol in
the presence of specific enzymes namely aldo–keto reductases and
carbonyl reductases catalysing a two-electron reduction of the
drug (Minotti et al, 1995). These metabolic pathways of DOX play
an important role in the detoxication steps (Bernardini et al, 1991;
Ferrazzi et al, 1991), although doxorubicinol can also contribute to
the development of the dose-limiting cardiotoxicity (Olson et al,
1988; Forrest et al, 2000).
On the other hand, there is an increasing body of evidence
that the reductive activation of antitumour drugs, for example,
mitomycin C, tirapazamine and indoloquinone, could result in
covalent binding to DNA (McGuinness et al, 1991; Adams
and Stratford, 1994; Bailey et al, 2001) and lead to the important
increase in the cytotoxic activity of these compounds against
tumour cells (Patterson et al, 1995, 1997; Chinje et al, 1999;
Cowen et al, 2003). Many investigations are also focused on
the bioreductive activation of DOX (Bartoszek and Wolf, 1992;
Taatjes et al, 1997; Bartoszek, 2002). It was evidenced that, in the
presence of reductive agents or oxidoreductases, DOX forms
reactive intermediates capable of alkylation or crosslinking
binding with DNA (Cummings et al, 1991; Cullinane et al, 1994;
Skladanowski and Konopa, 1994). Doxorubicin adducts with
cellular DNA have been shown to be formed from reduction of
the drug in vitro and to involve the C7 position of the reductively
activated quinone methide and guanine-base position of DNA
(Cullinane et al, 1994). It was also evidenced that the covalent
linkage of the drug to one of the DNA strand increases remarkably
the stability of the duplex in comparison with the complex with
noncovalently bound DOX (Zeman et al, 1998). The relevance of
reductive activation of DOX by CPR for increasing cytotoxic
activity of this drug towards sensitive human breast cell line
MCF-7 has been also demonstrated using purified rat CPR
(Bartoszek and Wolf, 1992). It was also evidenced that the
transfection of human CPR cDNA into Chinese hamster ovary
cells increased the cytotoxic activity of DOX by 1.8–3.3-fold
(Sawamura et al, 1996). There are also literature data reporting
that the overexpression of CPR in VP79 Chinese hamster
fibroblasts (Schmalix et al, 1996) and in stably transfected clones
of MDA231 human breast cancer cells (Ramji et al, 2003) did not
confer enhanced sensitivity of these cells to the cytotoxicity of
DOX. Additionally, because it is proposed that CPR could also play
an important role in the detoxication pathway via the reductive
deglycosylation of DOX, some studies were focused on studying
the cytotoxic activity against tumour cells presenting decreased
CPR expression. It was shown that the suppression of CPR activity
in human non-small cell lung carcinoma EBC-1 and PC9 and
BALM3 lymphoma cell lines realized via pharmacological methods
as well as the antisense approach resulted in increasing cytotoxic
activity of DOX (Niitsu et al, 2000).
The objective of this study was to examine the role of reductive
activation of DOX by the human liver CPR in increasing its
cytotoxic activity especially in regard to MDR tumour cells. For
this purpose, the ability of DOX to inhibit the growth of human
promyelocytic leukaemia HL60 cell line as well as its MDR sublines
exhibiting two different phenotypes of MDR related to the
overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/
DOX) was investigated in the presence of exogenously added CPR
and NADPH. It was found that upon CPR catalysis, DOX
underwent only the redox cycling (at low NADPH concentration)
or the metabolic conversion (at high NADPH concentration). Our
assays showed that the presence of CPR catalysing only the redox
cycling of DOX had no effect in increasing its cytotoxicity against
sensitive and MDR tumour cells. In contrast, an important increase
in the cytotoxic activity of DOX after its metabolic conversion by
CPR was observed against sensitive HL60 as well as resistant HL60/
VINC and HL60/DOX cells.
MATERIALS AND METHODS
Reagents
NADPH, superoxide dismutase (SOD) and vincristine were
obtained from Sigma Chemical Co. (St Louis, MO, USA).
Doxorubicin was kindly provided by Pharmacia-Upjohn (Milano,
Italy). CPR from human liver was obtained from C Roland Wolf’s
Laboratory, Ninewells Hospital and Medical School (Dundee, UK)
according to the procedure described earlier (Smith et al, 1994).
Cell culture
HL60 human promyelocytic leukaemia line (Division of Biology,
Kansas State University, Manhattan, KS 66506, USA) and its
resistant sublines HL60/VINC (overexpressing P-glycoprotein)
(McGrath et al, 1989) and HL60/DOX (overexpressing MRP1)
(Marsh et al, 1986; Krishnamachary and Center, 1993) were
cultured. The cells were grown in RPMI 1640 (Gibco Limited,
Paisley, UK) medium supplemented with 2mM glutamine and
10% FBS (Gibco Limited, Paisley, UK) at 371C in a humidified
atmosphere of 95% air and 5% CO2. HL60/VINC cells were
cultured in the presence of 10nM vincristine and HL60/DOX cells
in the presence of 200nM DOX. All cultures (HL60, HL60/VINC,
HL60/DOX) initiated at a density of 10
5cellsml
 1 grew exponen-
tially to about 10
6cellsml
 1 in 72h. They were counted before the
assay using a Burker hemocytometer. Cell viability was assessed by
trypan blue exclusion.
Enzymatic studies
Stock solutions of DOX and NADPH (C0¼10
 3 M) were prepared
just prior to use. Concentrations were determined by diluting stock
solutions in water to approximately 50mM and using an extinction
coefficient of e480¼11500 M
 1cm
 1 and e340¼6220M
 1cm
 1 for
DOX and NADPH, respectively.
The reaction mixtures in 0.01 M K2HPO4/KH2PO4 buffer (pH
7.25) contained 0–100mM DOX, 0–2000mM NADPH, 0–0.1mgml
 1
CPR and 0 or 500Uml
 1 SOD. All the reactions were initiated by
the addition of CPR and conducted at 371C. Absorption spectra of
DOX were recorded at the indicated time points in the visible region
(330–800nm). NADPH oxidation was measured at l¼340nm
using an extinction coefficient of e¼6220 M
 1cm
 1. Absorption
measurements were made on a Marcel E330 spectrophotometer.
Cytotoxicity assays
For each cell line, the cytotoxic effects of DOX were determined
by incubating cells (10
5) with 10 different concentrations of the
compound for 72h in standard 48-well plates. The enzymatic
samples contained, for DOX acting in redox cycling: 100mM DOX,
100–350mM NADPH and 0.1mgml
 1 CPR; for DOX under-
going reductive conversion: 100mM DOX, 500mM–2mM NADPH,
0.1mgml
 1 CPR and 0 or 500Uml
 1 SOD (0.01 M K2HPO4/
KH2PO4 buffer, pH 7.25 at 371C). The appropriate volumes of the
enzymatic sample were added directly to the cell suspensions to
yield DOX concentration varying in the ranges of 0.1–100nM,
5n M–3mM and 5nM–5mM for HL60, HL60/VINC and HL60/DOX
cells, respectively. Control assays were carried out for buffer alone
at the highest percentage employed in culture medium (2%, vv
 1)
and for NADPH alone (2, 60 and 100mM in the case of HL60, HL60/
VINC and HL60/DOX cells, respectively) or CPR alone (0.1, 3 and
5mgml
 1 in the case of HL60, HL60/VINC and HL60/DOX cells,
respectively) at the highest concentrations used in in vitro studies.
The values of DOX concentration required to inhibit by 50% (IC50)
the cell growth were determined by counting the viable cells in the
presence of trypan blue using a Burker hemocytometer.
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sStatistical analysis
Results are presented as the mean7s.d. of five independent
experiments. Statistical analysis of the significance level of the
differences observed between IC50 values found for nonactivated
and activated DOX was carried out using Student’s t-test. Po0.05
was considered as a significant difference.
RESULTS
Reduction of DOX by CPR-spectroscopic studies
The structure of DOX is presented in Figure 1. The effect of
NADPH concentration on the enzymatic reduction of DOX by CPR
has been studied in a wide range (100mM, 250mM, 300mM, 350mM,
500mM,1 m M,2 m M). Figure 2 illustrates the representative
absorption spectra of samples recorded during the incubation of
100mM DOX with 0.1mgml
 1 CPR in the presence of NADPH at
low concentration (obtained at 100mM NADPH) (Figure 2A) or at
high concentration (obtained at 500mM NADPH) (Figure 2B).
Figure 2C shows results found for the sample containing
100mM DOX, 500mM NADPH, 0.1mgml
 1 CPR and additionally
500Uml
 1 SOD. The absorption measurements at selected absorp-
tion wavelengths, 340 and 480nm, were also carried out conti-
nuously for each sample studied. These selected wavelengths
represent the maximum absorption wavelengths for NADPH
(340nm) and DOX (480nm).
It was found that at low NADPH concentration lying in the
range of 100–350mM, a very important decrease in the absorption
intensity at 340nm (A340nm) was observed immediately after the
addition of CPR indicating that DOX caused a high stimulation
of NADPH oxidation catalysed by CPR, but no changes were
observed in the absorption spectra of DOX up to 3h (the presented
data show the absorption spectra recorded for the first 60min
only). In contrast, at high NADPH concentration (500mM–2mM),
after the addition of CPR, not only the decrease in A340nm was
observed but after about 2min the important decrease in A480nm
was also observed followed by further modifications of absorption
spectra of DOX. About 5min after the addition of CPR, the
important shift of the absorption band of DOX was observed
indicating the modifications in the chromophore part of the drug.
During the prolonged incubation (1h), the aglycone precipitation
occurred. It was also found that after the addition of SOD to the
enzymatic samples containing CPR and high concentrations of
NADPH (500mM–2mM), only the rapid oxidation of NADPH
occurred, but no changes were observed in the absorption spectra
of DOX (Figure 2C).
The cytotoxic activity of DOX towards HL60 cell line and
its multidrug-resistant sublines: HL60/VINC and HL60/
DOX
The ability of DOX to inhibit the growth of human promyelocytic
leukaemia HL60 cell line as well as its MDR sublines exhibiting two
different phenotypes of MDR related to the overexpression of
P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX) was studied in
the presence or in the absence of exogenously added NADPH and
CPR. All control cells proliferated during 72h. The growth rate of
the parent cells (HL60) was comparable with both resistant cells
used in the study (HL60/VINC and HL60/DOX). All cultures
initiated at a density of 10
5 cellsml
 1 grew to about 10
6 cellsml
 1
(control count) in 72h. The cytotoxic effect of DOX was
determined by incubating cells (10
5) with 10 different concentra-
tions of DOX for 72h. In calculating cell growth (% of control),
untreated cells were used as the control. The results obtained for
each cell line are illustrated in Figure 3. Additional assays carried
out for buffer alone, NADPH alone or CPR alone at the highest
concentrations used in in vitro studies showed that these agents
had no effect on cell growth. In all, 100% cell growth of control
HL60, HL60/VINC and HL60/DOX was observed at the highest
percentage of buffer employed in the culture medium (2%, vv
 1)
as well as at highest concentrations of NADPH (2, 60 and 100mM in
the case of HL60, HL60/VINC and HL60/DOX cells, respectively)
or CPR used (0.1, 3 and 5mgml
 1 in the case of HL60, HL60/VINC
and HL60/DOX cells, respectively). Control assays carried out for
enzymatic samples containing simultaneously NADPH and CPR
at the same concentration ranges showed that they have neither
any effect on cell growth (100% of control cell growth was also
observed, data not presented).
Our results (Figure 3A) showed that the incubation of HL60
cells with DOX pretreated in the presence of CPR and low
NADPH concentration (100–350mM) had no effect in increasing
its cytotoxicity in comparison with DOX alone. In contrast, the
incubation of HL60 cells with DOX pretreated with CPR at high
NADPH concentration (500mM–2mM) resulted in an important
increase in cell growth inhibition. Higher NADPH concentrations
used in enzymatic samples (1, 2mM) did not result in further
increase in DOX cytotoxic activity in comparison to results found
employing samples that contained 500mM NADPH. The increasing
effect in cytotoxic acivity of DOX was conserved even when the
drug was added 10min after the preincubation step with NADPH
and CPR (data not presented). In contrast, this effect was
completely abolished in the presence of 500Uml
 1 SOD added
to the enzymatic sample.
The same results were found for multidrug-resistant sublines:
HL60/VINC and HL60/DOX (Figure 3B and C). The pretreatment
of DOX in the presence of CPR and low NADPH concentration
(100–350mM) had no effect in increasing its cytotoxicity against
resistant tumour sublines. In contrast, an important increase in
the cytotoxic activity of DOX after its pretreatment with CPR at
high NADPH concentration (500mM–2mM) was observed against
HL60/VINC as well as HL60/DOX cells. Similarly to results found
for sensitive HL60 cells, higher NADPH concentrations used
in enzymatic samples (1, 2mM) did not result in further increase
in DOX cytotoxic activity against both resistant cell lines in
comparison to results found employing samples that contained
500mM NADPH.
IC50 values (DOX concentrations required to inhibit 50% of
cell growth) are summarised in Table 1. As can be seen, the
important decrease in IC50 values was observed for DOX activated
by CPR in comparison to DOX alone (nonactivated) for both
sensitive and resistant cell lines examined. The most important
decrease in IC50 value was observed in the case of HL60/DOX cells.
IC50 value found for DOX activated was equal to 5717199nM vs a
value of 16447408nM found for DOX alone (nonactivated)
(Po0.0001).
O
O
OH
OH OCH3 O
OH
COCH2OH
O H3C
HO
H2N
Figure 1 Structure of doxorubicin (DOX).
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sAdditional studies performed for vincristine, a nonbioreductive
antitumour agent, showed that this compound was not able to
stimulate NADPH oxidation in the presence of CPR and no
modification in cytotoxic activity of vincristine was observed in
the presence of exogenously added CPR against HL60 as well as
HL60/VINC and HL60/DOX cells (data not presented).
DISCUSSION
The ability of neoplastic cells to develop MDR to chemotherapeutic
agents (e.g. anthracyclines, vinca alkaloids, podophylotoxins,
colchicine) structurally dissimilar and having different intracel-
lular targets constitutes the major problem in cancer therapy
(Chaudhary and Roninson, 1993). The MDR transporters (e.g.
P-glycoprotein, MRP1) are responsible for the active efflux of
drugs out of resistant cells resulting in the decreased intracellular
accumulation insufficient to inhibit resistant cell proliferation
(Gottesman and Pastan, 1993; Loe et al, 1996). It was reported by
several researchers that DOX enters into sensitive cells and binds
especially to the nucleus (Tarasiuk et al, 1989; Tarasiuk and
Garnier-Suillerot, 1992; Skladanowski and Konopa, 1994; Taatjes
and Koch, 2001; Cutts et al, 2003). It has also been presented that
in the case of nonactivated DOX, the kinetics of cellular uptake was
comparable with the rate of the efflux by MDR exporting pumps
(P-glycoprotein and MRP1). Consequently, a drastic decrease in
the cellular accumulation of the drug determining its cytotoxic
activity was observed (Mankhetkorn et al, 1996; Marbeuf-Gueye
et al, 1998, 1999). Furthermore, there is an increasing number of
data demonstrating that the enzymatic activation of DOX results in
the formation of reactive intermediates capable of alkylation or
crosslinking binding with DNA (Cummings et al, 1991; Cullinane
et al, 1994; Skladanowski and Konopa, 1994). Taking these
findings together it would be assumed that oxidoreductases
involved in drug metabolic activation could generate reactive
intermediates of DOX able to irreversibly bind to DNA before
being removed from the resistant cells by MDR exporting pumps.
This approach could give a possibility to restore the activity of this
bioreductive antitumour agent against multidrug-resistant tumour
cells.
In this study, we investigated the role of reductive activation
of DOX by the human liver CPR in increasing its cytotoxic activity
against human promyelocytic leukaemia cells exhibiting two
different phenotypes of MDR related to the overexpression of
P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX). Our previous
results showed that the reduction of DOX by CPR and the
formation of metabolic intermediates did not occur in the absence
of oxygen (Bartoszek et al, 1999). However, low oxygen content
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Figure 2 Spectroscopic changes followed during incubation of DOX in enzymatic systems. The selected absorption wavelengths, 340 and 480nm,
represent the maximum absorption wavelengths for NADPH and DOX, respectively. The samples contained the following: (A) 100mM DOX, 100mM
NADPH and 0.1mgml
 1 CPR; (B) 100mM DOX, 500mM NADPH and 0.1mgml
 1 CPR; (C) 100mM DOX, 500mM NADPH, 0.1mgml
 1 CPR and
500Uml
 1 SOD. The measurements were carried out in 0.01 M K2HPO4/KH2PO4 buffer (pH 7.25) at 371C. The reactions were initiated by the addition of
CPR. Data shown are from a representative experiment.
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sfound often in solid tumours is rather not characteristic for
promyelocytic leukaemia studied in the work.
Spectroscopic studies performed during incubation of DOX
in enzymatic systems containing CPR and various amounts of
NADPH showed that the availability of NADPH as a cofactor
of enzymatic reactions was a crucial factor determining the route
of drug activation. The similar findings were also reported for
tirapazamine activation by CPR (Saunders et al, 2000). It is
proposed that NADPH could participate in forming a coupled
interactive system and in consequence constitute a control point in
drug activation by cellular oxidoreductases. It was found that at
low NADPH concentration lying in the range of 100–350mM,a
high stimulation of NADPH oxidation catalysed by CPR occurred
but no changes were observed in the absorption spectra of the
drug. It suggests that under these experimental conditions DOX
underwent only the redox cycling activation accompanied by the
rapid consumption of NADPH. In contrast, at higher NADPH
concentration the important shift of the absorption band of DOX
was observed indicating the modifications in the chromophore
part of the drug. Thus, under these conditions DOX was not only
very effective in NADPH stimulation but also concomitantly
underwent a multistage chemical transformation upon CPR
catalysis. It was found that the minimal concentration of NADPH
required for a metabolic activation of DOX occurring with the
modification of the chromophore part of the drug was equal to
500mM. It was also evidenced that the addition of SOD decom-
posing O2
K
abolished the reductive conversion of DOX by CPR
observed in the presence of high concentrations of NADPH
(500mM–2mM). It indicates that the first stage of DOX reduction
by CPR, undergoing reductive activation probably according to the
mechanism of the redox cycling, has the key importance for the
metabolic conversion of DOX. It seems that O2
K
could be involved
(directly or indirectly) in chemical transformations of DOX.
However, the exact role of O2
K
in further steps of the metabolic
conversion of DOX remains to be clarified. In Figure 4, schema
summarising the reduction of DOX by CPR under various
experimental conditions studied in the work are presented.
In the second part of the study, it was demonstrated that the
presence of CPR catalysing only the redox cycling of DOX had no
effect in modulating its cytotoxicity against sensitive HL60 as well
as resistant HL60/VINC and HL60/DOX cells in comparison to
DOX alone. Consequently, the formation of degradation products
of DOX having the same absorption spectra as the parent drug (e.g.
aglycone metabolites or doxorubicinol) and the contribution of
these products to cytotoxic activity should be rather excluded
because it is well known that DOX aglycone has no cytotoxic
activity and doxorubicinol was about 20 times less cytotoxic than
DOX towards tumour cells (Olson et al, 1988; Bernardini et al,
1991; Ferrazzi et al, 1991). Thus, it seems that the cytotoxic activity
observed in vitro at low NADPH concentration was caused only by
DOX regenerated in the redox cycling. In contrast, after a
metabolic conversion of DOX by CPR occurring at high NADPH
concentration (at least 500mM) an important increase in its
cytotoxic activity was observed against HL60 as well as HL60/
VINC and HL60/DOX cells. It should be rather excluded that
NADPH or CPR added exogenously could get into the cell. On the
basis of the results obtained with the aid of exogenous SOD (not
being able to penetrate across the plasma membrane) that
abolished completely the increasing effect in cytotoxic activity of
DOX observed in the same experimental conditions in the absence
of SOD, it should be rather proposed that DOX is activated outside
the cells by extracellularly added CPR. It is worth noting that the
data presented in the study (similar increase of about 2–3-fold in
the cytotoxic activity of DOX against resistant HL60/VINC and
HL60/DOX cells as it was observed in the case of sensitive HL60
cell line) suggest that this (these) metabolite(s) generated
extracellulary is (are) able to enter the cell and bind to cellular
targets before being extruded by MDR exporting pumps. At this
stage of our research, the nature of this (these) metabolite(s) is
unknown. It is evident that its (their) formation is related to the
modifications of the chromophore part of DOX resulting in the
important changes of its absorption spectrum. The data obtained
also evidenced that it was (they were) (a) relatively long-lived
specie(s) because the increasing effect in cytotoxic activity of DOX
was conserved even when the drug was added 10min after the
preincubation step with NADPH and CPR. Identification of this
(these) reactive metabolite(s) as well as investigating its (their) rate
of cellular accumulation, level of nuclear retention and rate of
active export by MDR exporting pumps (P-glycoprotein, MRP1)
Table 1 Cytotoxic activity of doxorubicin towards HL60 cell line and its
multidrug resistant sublines: HL60/VINC and HL60/DOX
IC50 (nM)
Cell line Doxorubicin nonactivated Doxorubicin activated
HL60 18.678.9 9.374.2
HL60/VINC 4387133 256768
a
HL60/DOX 16447408 5717197
b
IC50 is the doxorubicin (DOX) concentration required to inhibit 50% of cell growth.
The values represent mean7s.d. of five independent experiments. The significance
level of the differences observed (Students’s t-test).
aPo0.05;
bPo0.0001 vs values
found for DOX alone (nonactivated).
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order to clarify the role of reductive activation of DOX by cellular
oxidoreductases in the mode of action of this drug in regard to
resistant tumour cells. These studies are in progress in our
laboratory.
Presented data showed that the reductive activation of DOX by
exogenously added CPR resulted in the 2- to 3-fold increase in
cytotoxic activity of the drug (IC50 value were decreased from
18.678.9 to 9.374.2nM, from 4337133 to 256768nM and from
16447408 to 5717197nM in the case of HL60, HL60/VINC and
HL60/DOX, respectively), whereas HL60/VINC and HL60/DOX
cells were, respectively, 23- and 88-fold resistant compared to the
sensitive cells. However, taking into account that the plasma level
of DOX achievable clinically is in the range of 1–2mM as well as
that high drug concentrations could be responsible for severe
dose-dependent toxic side effects, it seems that the reported
decreases in IC50 values found for resistant cell lines (HL60/VINC
and HL60/DOX) could be of clinical importance for the treatment
of tumours resistant to classical chemotherapy. Having in mind
literature data, it was not surprising that the formation of reactive
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Figure 3 Cytotoxic activity of doxorubicin (DOX) towards (A) HL60 cells, (B) HL60/VINC cells and (C) HL60/DOX cells. The enzymatic samples
contained as follows: for DOX ‘recycling’: 100mM DOX, 100mM NADPH and 0.1mgml
 1 CPR; for DOX activated (undergoing reductive conversion):
100mM DOX, 500mM NADPH and 0.1mgml
 1 CPR; for DOX activatedþSOD: 100mM DOX, 500mM NADPH, 0.1mgml
 1 CPR and 500Uml
 1 SOD
(0.01 M K2HPO4/KH2PO4 buffer, pH 7.25; 371C). The appropriate volumes of the enzymatic sample were added directly to the cell suspension to yield the
DOX concentration varying in the range of 0.1–100nM,5n M–3mM and 5nM–5mM for HL60 (A), HL60/VINC (B) and HL60/DOX (C) cells, respectively.
The cytotoxic effect of DOX was determined by incubating cells (10
5) with 10 different concentrations of the compound for 72h. The data points are from
a representative experiment.
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cytotoxic activity against sensitive HL60 cells. The obtained results
are in agreement with data previously reported for human breast
tumour MCF-7 cells (Bartoszek and Wolf, 1992). However, it seems
that the importance of the presented data concerns the demonstra-
tion that the potentiation of DOX activity would also be obtained
in resistant cells overexpressing MDR exporting pumps able to
extrude drugs from the cell. Thus, it would be proposed that this
(these) reactive metabolite(s) generated by CPR is (are) able to
bind to cellular targets before being pumped out of the cell by
P-glycoprotein or MRP1. Furthermore, based on presented results,
it seems that the enhancement in cytotoxic activity of DOX in the
presence of exogenously added CPR and NADPH did not involve
additionally other specific resistance mechanisms.
According to the literature data, metabolic activation of drugs
can also undergo efficiently inside tumour cells. It is known that
intracellular CPR expression involved in the activation of
bioreductive agents can be modulated in cells by many internal
factors such as oxygen deficiency, intracellular pH changes and by
malignant transformations themselves (Adams and Stratford, 1994;
Forkert et al, 1996). The development of an enzyme-directed gene
therapy (GDEPT) approach targeted toward specific reductase
enzyme for antitumour drug bioactivation is also in progress in
many laboratories (Cowen et al, 2003). However, literature data
reported for some tumour cells overexpressing CPR showed the
lack of enhanced sensitivity of these cells to the cytotoxicity of
DOX (Schmalix et al, 1996; Ramji et al, 2003), whereas a study by
Niitsu et al (2000) reported that decrease in intracellular CPR level
increased DOX cytotoxicity. It suggests that the reductive
activation of DOX in situ in target cells by CPR could be
influenced by several cellular factors, for example, bioavailability
of NADPH, competitive metabolic pathways of the drug catalysed
by other enzymes depending on their cellular levels or rapid
decomposition of ROS and DOX free radicals by the antioxidant
defence system of the cell. In the presented study, the metabolic
activation of DOX occurred under well-controlled experimental
conditions and the obtained results indicate that the reactive
metabolite(s) formed extracellularly is (are) able to penetrate into
the cell and bind to intracellular targets before being decomposed.
Nevertheless, in further steps of the study it would be interesting to
also examine the intracellular activation of DOX in leukaemia cells
overexpressing CPR.
CONCLUSION
The data presented in the study suggest that the reductive
activation of DOX by exogenously added CPR constitutes a
possibility to potentiate the activity of this clinically important
drug against multidrug-resistant leukaemia cells. Having in mind
the relative stability of reactive intermediate(s) generated extra-
cellulary and its (their) ability to increase the cytotoxic activity of
the drug, the metabolic activation of DOX by exogenous CPR just
before being administrated might be perhaps taken into con-
sideration. However, the clinical significance of the presented
results obtained in the model system remains to be elucidated.
Therefore, further studies are needed to prove the potential
importance of the presented data in leukaemia therapy.
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